Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026
Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society 68th Annual Scientific Meeting
Axsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness Month
Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2026 Annual Meeting
Axsome Therapeutics Announces FDA Approval of AUVELITY® for the Treatment of Agitation Associated with Dementia due to Alzheimer's Disease
Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions
Axsome Therapeutics Initiates CLARITY Phase 3 Trial of Solriamfetol in Adults with Major Depressive Disorder with Excessive Daytime Sleepiness Symptoms
Syntholene Energy Corp. Appoints Former Suncor, Shell Operations Executive Marc Mageau to Advisory Board
